Forte Biosciences 2025 net loss widens as R&D costs surge
Overview
US biopharmaceutical firm's 2025 operating expenses more than doubled, driven by FB102 clinical trials
Net loss for 2025 widened compared to prior year
General and administrative expenses fell yr/yr due to lower professional and legal fees
Result Drivers
FB102 CLINICAL TRIALS - Co said higher R&D expenses were mainly due to increased manufacturing and clinical costs for FB102 Phase 2 and Phase 1b trials
PERSONNEL COSTS - R&D and G&A personnel-related expenses rose due to increased headcount and non-cash stock-based compensation
LOWER LEGAL FEES - General and administrative expenses fell mainly due to lower professional and legal advisory fees, including litigation and settlement expenses
Company press release: ID:nBw3GbyKPa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
FY Net Income |
| -$69.38 mln |
|
FY Basic EPS |
| -$4.71 |
|
FY Income From Operations |
| -$70.66 mln |
|
FY Operating Expenses |
| $70.66 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Forte Biosciences Inc is $61.00, about 131.8% above its March 30 closing price of $26.32
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
